Table 4.
The rates of SARS-CoV-2 infection causing pneumonia, requiring drug administration, and requiring hospitalization in children with IEI.
| n | Pneumonic | Hospitalized | ICU admission (n) | ||
|---|---|---|---|---|---|
| All | 71 | 15% | 17% | 1 | |
| Classification | |||||
| I. Combined immunodeficiencies | 7 | 29% | 29% | 0 | |
| II. Combined immunodeficiencies with syndromic features | 6 | 0% | 0% | 0 | |
| III. Predominantly antibody deficiencies | 19 | 21% | 26% | 1 | |
| IV. Diseases of immune dysregulation | 6 | 17% | 17% | 0 | |
| V. Congenital defects of phagocytes | 8 | 13% | 13% | 0 | |
| VI. Defects in intrinsic and innate immunity | 2 | 50% | 0% | 0 | |
| VII. Autoinflammatory diseases | 21 | 10% | 10% | 0 | |
| XI. Uncategorized IEIs | 2 | 0% | 50% | 0 | |
| Gender | |||||
| Male | 46 | 13% | 15% | 1 | |
| Female | 25 | 20% | 20% | 0 | |
| Age (y) | |||||
| <2 | 11 | 18% | 36% | 0 | |
| 2–5 | 16 | 19% | 6% | 0 | |
| 5–10 | 20 | 25% | 25% | 1 | |
| >10 | 24 | 4% | 8% | 0 | |
| Infection sources | Household transmission | 67 | 15% | 12% | 1 |
| Hospital visits | 4 | 25% | 100% | 0 | |
| SARS-CoV-2 Vaccination | |||||
| No | 45 | 16% | 18% | 1 | |
| Yes | 26 | 15% | 15% | 0 | |
| Pre-existing treatment | |||||
| Glucocorticoids | 15 | 7% | 27% | 0 | |
| Immunoglobulin replacement | 22 | 18% | 18% | 1 | |
| Biological agents | 8 | 0% | 13% | 0 | |
| Anti-infective drugs | 18 | 22% | 33%* | 0 | |
| Immunosuppressive drugs | 22 | 18% | 18% | 1 | |
| None | 9 | 11% | 0% | 0 | |
*p<0.05.